Cellectis (NASDAQ:CLLS) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?

Key Points

• Cellectis S.A. stock price recently crossed above its fifty-day moving average, trading at $2.57, an increase from its average of $2.25.
• Several analysts have issued mixed ratings for Cellectis, with Barclays lowering its price target to $4.00 and a consensus rating of "Buy."
• The company reported a revenue of $18.19 million for the last quarter, significantly exceeding analyst expectations, despite a negative earnings per share of ($0.24).

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) shares crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.25 and traded as high as $2.68. Cellectis shares last traded at $2.57, with a volume of 35,096 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays lowered their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $4.00.

Cellectis Stock Performance

The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The business has a 50 day simple moving average of $2.29 and a two-hundred day simple moving average of $1.71. The firm has a market cap of $143.96 million, a PE ratio of -3.16 and a beta of 3.03.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%.The business had revenue of $18.19 million during the quarter, compared to analysts' expectations of $10.07 million. As a group, equities research analysts forecast that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its stake in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after buying an additional 12,500 shares during the period. OLD Mission Capital LLC purchased a new position in shares of Cellectis during the first quarter valued at $31,000. Acadian Asset Management LLC grew its stake in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. Millennium Management LLC purchased a new position in Cellectis in the fourth quarter valued at about $962,000. Finally, Long Focus Capital Management LLC grew its stake in Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company's stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.